Xolair 150 MG/ML 1S
Ended Awarded Last action
- Contract number
- SPE2DR26FBTFH
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,106
Award facts
- Contract value 100% obligated
- $13,105.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $13,105.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml. This firm fixed-price delivery order, awarded on December 9, 2025, with an ultimate completion date of January 7, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR and valued at $499,999,999 through December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the Defense Logistics Agency's broader $30.3 billion PPV-G GEN V acquisition strategy, which establishes multiple regional prime vendor contractors to support recurring medical supply needs of military healthcare facilities worldwide. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, with documented delivery orders ranging from under $100 to exceeding $115,000. The PPV-G GEN V contract structure, featuring a 30-month base period with three 30-month option periods, positions DMS Pharmaceutical Group to fulfill the diverse and specialized pharmaceutical requirements of Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FBTFH?
SPE2DR26FBTFH was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 9, 2025.
How much is contract SPE2DR26FBTFH worth?
The government has obligated $13,106 on SPE2DR26FBTFH.
Is contract SPE2DR26FBTFH an order under another contract?
Yes. SPE2DR26FBTFH is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTFH competed?
The extent of competition for SPE2DR26FBTFH was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award